One of only two FGF21 analogs tested in a study of biopsy-confirmed NASH patients, pegbelfermin administered daily or weekly for 16 weeks reduced triglycerides by 5% and LDL-cholesterol by about 10% from baseline, while increasing HDL-cholesterol by about 12% and adiponectin by 15% (245). The gene discussed is FGF21; the disease is metabolic dysfunction-associated steatohepatitis.